EstoniaTuberculosis profile
Population  2017 1.3 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.012 (0.012–0.012) 0.93 (0.91–0.95)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.21 (0.15–0.28)
Incidence  (includes HIV+TB) 0.2 (0.17–0.23) 15 (13–17)
Incidence (HIV+TB only) 0.017 (0.015–0.02) 1.3 (1.1–1.5)
Incidence (MDR/RR-TB)** 0.071 (0.046–0.1) 5.4 (3.5–7.7)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.062 (0.048–0.075) 0.069 (0.055–0.083)
Males <0.01 (<0.01–<0.01) 0.12 (0.094–0.15) 0.13 (0.1–0.15)
Total 0.015 (0.013–0.018) 0.18 (0.15–0.21) 0.2 (0.17–0.23)
TB case notifications, 2017  
Total cases notified 175
Total new and relapse 171
          - % tested with rapid diagnostics at time of diagnosis 78%
          - % with known HIV status 92%
          - % pulmonary 96%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.08 (0.06–0.09)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 13 8%
          - on antiretroviral therapy 12 92%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  45
(33–56)
Estimated % of TB cases with MDR/RR-TB 21% (14–29) 52% (30–74)  
% notified tested for rifampicin resistance 86% 72% 147
MDR/RR-TB cases tested for resistance to second-line drugs   34
Laboratory-confirmed cases MDR/RR-TB: 37, XDR-TB: 9
Patients started on treatment **** MDR/RR-TB: 35, XDR-TB: 9
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 80% 166
Previously treated cases, excluding relapse, registered in 2016 0% 1
HIV-positive TB cases registered in 2016 94% 18
MDR/RR-TB cases started on second-line treatment in 2015 71% 31
XDR-TB cases started on second-line treatment in 2015 33% 9
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 1.2
Funding source: 100% domestic,  international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-02-21 Data: www.who.int/tb/data